Mankind Pharma’s revolves around developing, manufacturing, and marketing affordable, high-quality pharmaceutical and consumer healthcare products, with a focus on accessibility and scale.
Product Portfolio:
Offers a diverse range of generics, branded generics, and specialty drugs across therapeutic areas like anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, dermatology, and respiratory.
Consumer healthcare products include condoms (Manforce), pregnancy test kits (Prega News), and emergency contraceptives (Unwanted-72), contributing significantly to revenue.
Market Strategy:
Strong domestic presence, with India accounting for ~80% of revenue; exports to 34 countries in Asia, Africa, and the Middle East.
Strategic acquisitions, like Bharat Serums and Vaccines (2024, ₹13,630 crore), expand high-margin segments like women’s health and fertility.
Revenue Model:
Primarily B2B (business-to-business) through sales to distributors and pharmacies, supplemented by direct-to-consumer OTC products.
Revenue for FY25: ₹12,207 crore, with a profit of ₹2,011 crore, driven by high-volume, low-cost generics and growing consumer healthcare sales.
Sustainability and Scale:
Emphasizes scalable operations with low-cost production and a lean supply chain.
Invests in sustainability initiatives and community health programs to enhance brand trust.
This model combines volume-driven generics, strategic innovation, and aggressive market outreach to maintain Mankind’s position as India’s fourth-largest pharma company by sales.
Affordability and Accessibility:
Focuses on price-disruptive generics, targeting cost-conscious markets, especially rural and semi-urban India.
Leverages a vast distribution network of over 16,000 stockists and 10,000+ field staff to ensure deep market penetration.
Manufacturing and R&D:
Operates 30 manufacturing facilities in India, with USFDA-approved plants for regulated markets.
Six R&D centers drive innovation, developing complex generics and specialty drugs like Dydrogesterone (Dydroboon).
Backward integration ensures cost efficiency and quality control.
Product Portfolio:
Offers a diverse range of generics, branded generics, and specialty drugs across therapeutic areas like anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, dermatology, and respiratory.
Consumer healthcare products include condoms (Manforce), pregnancy test kits (Prega News), and emergency contraceptives (Unwanted-72), contributing significantly to revenue.
Market Strategy:
Strong domestic presence, with India accounting for ~80% of revenue; exports to 34 countries in Asia, Africa, and the Middle East.
Strategic acquisitions, like Bharat Serums and Vaccines (2024, ₹13,630 crore), expand high-margin segments like women’s health and fertility.
Revenue Model:
Primarily B2B (business-to-business) through sales to distributors and pharmacies, supplemented by direct-to-consumer OTC products.
Revenue for FY25: ₹12,207 crore, with a profit of ₹2,011 crore, driven by high-volume, low-cost generics and growing consumer healthcare sales.
Sustainability and Scale:
Emphasizes scalable operations with low-cost production and a lean supply chain.
Invests in sustainability initiatives and community health programs to enhance brand trust.
This model combines volume-driven generics, strategic innovation, and aggressive market outreach to maintain Mankind’s position as India’s fourth-largest pharma company by sales.
Affordability and Accessibility:
Focuses on price-disruptive generics, targeting cost-conscious markets, especially rural and semi-urban India.
Leverages a vast distribution network of over 16,000 stockists and 10,000+ field staff to ensure deep market penetration.
Manufacturing and R&D:
Operates 30 manufacturing facilities in India, with USFDA-approved plants for regulated markets.
Six R&D centers drive innovation, developing complex generics and specialty drugs like Dydrogesterone (Dydroboon).
Backward integration ensures cost efficiency and quality control.
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。